NTx Bio

We are excited to officially introduce the NTxscribe® FLEX, a flexible benchtop RNA production system built on our proven NTxscribe® CORE technology and designed to extend its capabilities with greater control and customizability for early-stage development and process optimization.   FLEX is designed for researchers and process development teams who need more control over RNA production and the ability to tailor workflows without the complexity of traditional manufacturing scale-up.   It enables: - Flexible, customizable RNA production to meet your target needs - Automated IVT synthesis from DNA template through initial purification - Continuous-flow processing which automates production and eliminates the need for “good hands” - Steady state substrate supply, continuous waste removal, low shear stress and short residence time delivered unparalleled product quality - A compact benchtop system and single use, no product contact configuration reduces facility and resource cost and all but eliminates change over time   As RNA therapeutics advance, manufacturing remains a major bottleneck. Traditional batch processes can slow development and make scale-up costly and complex. FLEX is designed to help bridge that gap, supporting translational research today as well as future GMP-scale production.   Whether you're working on mRNA, saRNA, personalized cancer vaccines, or cell and gene therapy applications, FLEX is designed to fit into your development workflow.   NTxscribe® FLEX-RUO will be available in late summer 2026. FLEX-GMP expected in early 2027. Preorders available now for priority shipment.   📄 Read the full press release: https://lnkd.in/gcrkP2DB ➡️ Preorder NTxscribe® FLEX today: https://lnkd.in/eYK_YHPi   #RNA #mRNA #saRNA #Biomanufacturing #Biotechnology #ProcessDevelopment #RNATherapeutics

The molecule you produce is the molecule your biology has to work with. RNA quality isn't just a manufacturing consideration. It's a biological one. RNA degradation and dsRNA contamination can introduce variables that downstream development must account for. For the applications pushing RNA biology forward, this matters most: Complex RNA constructs need to arrive complete. A truncated molecule may not function as intended because key biological mechanisms depend on the full sequence being intact. Personalized cancer vaccines are patient-specific by definition. The highest quality RNA needs to be made reliably, every run, with fast, clean changeover between constructs. Cell reprogramming requires RNA that drives precise biological outcomes. Product quality directly shapes what the cell does. This is why NTx Bio designed its process to help minimize sources of RNA degradation from the moment of synthesis, rather than relying solely on downstream cleanup. When the manufacturing science is right, the biology becomes possible. Learn more at ntxbio.com #RNATherapeutics #CancerVaccines #CellTherapy #TheScienceBehindNTx #NTxBio

How much DNA template do you need for your next IVT run? The NTx Bio DNA Template Calculator helps researchers quickly determine the amount of linearized DNA template required for an NTxscribe® IVT reaction. Just enter your: 🧬 DNA template length 🧪 DNA concentration The calculator does the rest. Whether you're planning your next run or optimizing an existing workflow, it's a simple way to save time and move forward with confidence. Access the calculator & try it for yourself: https://lnkd.in/gUsKMY8K #RNAScience #mRNA #IVT #LabAutomation #Biomanufacturing #LifeSciences

RNA is one of the most powerful molecules in biology, and one of the most fragile. From the moment it's transcribed, RNA is vulnerable. IVT chemistry, shear forces from handling, and time in solution all work against it. The longer a construct is, the more surface area there is for something to go wrong. This is the scientific reality NTx Bio built around. Our approach starts with a simple principle: the less time RNA spends exposed to synthesis and purification chemistry, and the gentler the process conditions, the higher the integrity of what comes out the other end. That means controlling residence time. Minimizing shear. Moving RNA out of the reaction environment as quickly as possible and into purification, continuously, not in a batch collected hours later. Protecting RNA isn't a downstream QC problem. It's an upstream engineering decision. Learn more: https://ntxbio.com/ #RNAScience #mRNA #Biomanufacturing #TheScienceBehindNTx #NTxBio

Nature Reviews Drug Discovery just published an in-depth look at what it will take to get mRNA therapeutics from vaccines to a broader class of treatments, and manufacturing quality is one of the central challenges. The review covers a decade of clinical progress across enzyme replacement therapies, personalized cancer immunotherapies, genome-editing approaches, and immune cell reprogramming via CAR-T. The clinical momentum is real, with candidates from Moderna, BioNTech, Intellia, and Beam Therapeutics advancing into Phase II and III trials. But the authors are clear that mRNA purity, dsRNA contamination, and scalable production remain barriers that have to be solved for mRNA therapeutics 2.0 to deliver on its promise. For applications like enzyme replacement and personalized neoantigen vaccines, the manufacturing platform isn't a downstream consideration, it's a gating factor. These aren't abstract problems. They're the exact ones NTx Bio was built to solve, reduced degredation through short bioreactor residence times, low shear by leveraging true continuous flow, and a closed, single-use system that automates manufacturing from synthesis through purification. The science is no longer the failure point. Your traditional manufacturing process can’t keep up. Access the article here: https://lnkd.in/dqWWj9s3 #mRNA #mRNATherapeutics #Biomanufacturing #LifeSciences #Biotech

A recent opinion piece in The New York Times highlights a pivotal shift in medicine. Written by Jeff Coller, PhD, who directs the RNA Innovation Center at Johns Hopkins University and serves on NTx’s Scientific Advisory Board, the article reflects on a child born with a severe rare disease who was treated with a personalized CRISPR-based therapy, designed and delivered in a matter of months. Today, he’s thriving. The science is no longer the limiting factor. Advances in gene editing and mRNA have made it possible to develop highly targeted, patient-specific therapies, yet these breakthroughs remain the exception, not the standard. The constraint is infrastructure. If gene editing is to function like molecular surgery, manufacturing must evolve to match. It must be fast, flexible, and patient specific. Traditional large batch biomanufacturing was not designed for this paradigm. NTx Bio is focused on enabling rapid, automated, small batch RNA manufacturing to support the transition from one off breakthroughs to scalable clinical practice. On-demand, decentralized production models will be essential to making therapies viable for ultra-rare conditions and broader patient populations alike. The science is ready. Manufacturing must catch up. Personalized medicine will not scale until manufacturing does. Learn more about NTx: www.ntxbio.com Read the article here: https://lnkd.in/dZhMyeUu #Biotechnology #mRNA #PrecisionMedicine #RareDisease #Biomanufacturing #CellAndGeneTherapy

The World Vaccine Congress is underway! Our CEO, Joan Haab, and Director of Field Application Science, Nadiezda Fernandez Oropeza, PhD, have been connecting with peers and partners at our networking table, showcasing how NTx Bio is advancing the future of biomanufacturing. Joan also took the stage for Biomanufacturing Reinvented: Powering the Future of Medicine, sharing key insights on scalable, flexible manufacturing, and the conversation isn't over yet. Tomorrow, she'll be leading another session you won't want to miss: Industrializing Personalized RNA: Continuous-Flow Manufacturing to Compress Time, Cost, and Risk  Room 201, Level 2 | April 2 at 9:10 AM If you're attending, come hear how NTx is turning the future of personalized medicine into a manufacturing reality. ➡️ Learn more: https://lnkd.in/gRWa8T6q #WorldVaccineCongress #Biomanufacturing #Vaccines #Biotech

What could your team do with days of RNA time back? Traditional batch RNA manufacturing can take 24–72 hours, with multiple holds and manual interventions. NTxscribe® delivers purified RNA in ~2.5 hours using a continuous flow process. Designed for teams that want: - Faster iteration - Fewer bottlenecks - More control over their schedules Your science moves fast, your RNA production should too. ➡️ Connect with our team to learn more: https://lnkd.in/gGQf9T44 #Biotech #RNA #NTxscribe #ProcessDevelopment

RNA programs rarely stall due to lack of ideas. They stall when iteration takes too long. NTxscribe® helps teams shorten build test cycles, move quickly between constructs, and generate RNA on demand. More runs. Less waiting. Faster learning. That is how breakthroughs happen. 🔗 Discover NTxscribe®: https://lnkd.in/gGQf9T44 #RNAresearch #mRNA #LabAutomation #BiotechInnovation #SyntheticBiology #LifeSciences

NTx Bio is attending the The World Vaccine Congress Washington 2026, taking place March 30 – April 2 in Washington, D.C.   As one of the leading global gatherings for the vaccine community, the event brings together scientists, industry leaders, and innovators to explore advancements across the full vaccine value chain, from R&D and clinical trials to manufacturing and global access.   Our team, including Joan Haab, PhD, CEO, Matthew Phillips, SVP, Strategic Alliances, and Nadiezda Fernandez Oropeza, PhD, Director, Field Application Science, will be onsite and looking forward to connecting with industry peers and discussing the future of vaccine innovation.   If you’ll be attending and would like to connect, feel free to reach out to our team via LinkedIn. Learn more: https://lnkd.in/ewHGcf3   #WorldVaccineCongress #Vaccines #PublicHealth #IndustryInnovation